Abstract

Histone H2AX plays a key role in DNA damage signalling in the surrounding regions of DNA double-strand breaks (DSBs). In response to DNA damage, H2AX becomes phosphorylated on serine residue 139 (known as γH2AX), resulting in the recruitment of the DNA repair effectors 53BP1 and BRCA1. Here, by studying resistance to poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2-deficient mammary tumours, we identify a function for γH2AX in orchestrating drug-induced replication fork degradation. Mechanistically, γH2AX-driven replication fork degradation is elicited by suppressing CtIP-mediated fork protection. As a result, H2AX loss restores replication fork stability and increases chemoresistance in BRCA1/2-deficient tumour cells without restoring homology-directed DNA repair, as highlighted by the lack of DNA damage-induced RAD51 foci. Furthermore, in the attempt to discover acquired genetic vulnerabilities, we find that ATM but not ATR inhibition overcomes PARP inhibitor (PARPi) resistance in H2AX-deficient tumours by interfering with CtIP-mediated fork protection. In summary, our results demonstrate a role for H2AX in replication fork biology in BRCA-deficient tumours and establish a function of H2AX separable from its classical role in DNA damage signalling and DSB repair.

Histone H2AX has a known role in DNA damage repair but interestingly, its loss is associated with resistance to poly(ADP-ribose) polymerase (PARP) inhibition in BRCA-deficient tumours. Here, the authors identify a role of γH2AX in the degradation of replication forks and demonstrate that H2AX loss drives PARP inhibitor resistance via increased stressed fork stability in BRCA-deficient tumours.

Details

Title
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours
Author
Dibitetto, Diego 1   VIAFID ORCID Logo  ; Liptay, Martin 2 ; Vivalda, Francesca 3   VIAFID ORCID Logo  ; Dogan, Hülya 2 ; Gogola, Ewa 4 ; González Fernández, Martín 2   VIAFID ORCID Logo  ; Duarte, Alexandra 4 ; Schmid, Jonas A. 3   VIAFID ORCID Logo  ; Decollogny, Morgane 2   VIAFID ORCID Logo  ; Francica, Paola 2 ; Przetocka, Sara 3 ; Durant, Stephen T. 5 ; Forment, Josep V. 5 ; Klebic, Ismar 6 ; Siffert, Myriam 6 ; de Bruijn, Roebi 4 ; Kousholt, Arne N. 7   VIAFID ORCID Logo  ; Marti, Nicole A. 2 ; Dettwiler, Martina 6 ; Sørensen, Claus S. 8   VIAFID ORCID Logo  ; Tille, Jean-Christophe 9 ; Undurraga, Manuela 10 ; Labidi-Galy, Intidhar 11   VIAFID ORCID Logo  ; Lopes, Massimo 3   VIAFID ORCID Logo  ; Sartori, Alessandro A. 3   VIAFID ORCID Logo  ; Jonkers, Jos 4   VIAFID ORCID Logo  ; Rottenberg, Sven 12   VIAFID ORCID Logo 

 University of Bern, Institute of Animal Pathology, Vetsuisse Faculty, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); University of Bern, Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Department of Experimental Oncology, Milan, Italy (GRID:grid.4527.4) (ISNI:0000 0001 0667 8902) 
 University of Bern, Institute of Animal Pathology, Vetsuisse Faculty, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); University of Bern, Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157) 
 University of Zürich, Institute of Molecular Cancer Research, Zürich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650) 
 The Netherlands Cancer Institute, Division of Molecular Pathology, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Oncode Institute, Amsterdam, The Netherlands (GRID:grid.499559.d) 
 AstraZeneca, DDR Biology, Bioscience, Oncology R&D, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381) 
 University of Bern, Institute of Animal Pathology, Vetsuisse Faculty, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157) 
 Oncode Institute, Amsterdam, The Netherlands (GRID:grid.499559.d); University of Copenhagen, Biotech Research and Innovation Centre, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X) 
 University of Copenhagen, Biotech Research and Innovation Centre, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X) 
 Hôpitaux Universitaires de Genève, Division of Clinical Pathology, Department of Diagnostics, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812) 
10  Hôpitaux Universitaires de Genève, Division of Gynecology, Department of Pediatrics and Gynecology, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812) 
11  Swiss Cancer Center Leman, Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland (GRID:grid.511014.0); Rue Gabrielle Perret-Gentil, Department of Oncology, Hôpitaux Universitaires de Genève, 4, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812) 
12  University of Bern, Institute of Animal Pathology, Vetsuisse Faculty, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); University of Bern, Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); The Netherlands Cancer Institute, Division of Molecular Pathology, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393) 
Pages
4430
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3059661583
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.